West of England AHSN Risk Stratification Tool
The medication safety dashboard is a tool being developed to support the West of England AHSN to identify best practice, opportunities for improvement and supporting spread and adoption across the AHSN.
It utilises a set of prescribing indicators that have been developed as part of a programme of work to promote safer use of medicines, including prescribing, dispensing, administration and monitoring.
The purpose of the indicators are to support reductions in hospital admissions that may be associated with prescribing, to reduce the risk of avoidable medicines related harms and to quantify patients at potentially increased medicines related safety risk.
- The content is based on consideration of the medicines safety related indicators that are available in the growing number of ‘dashboards’, related information sources and data sets available.
- The RST only contains a selected number of medicines safety indicators for the purpose of supporting local focus, with input from across the AHSN on choice of indicators and content.
- This RST approach is aimed at developing and supporting collaborative based working across the AHSN on improving medication safety on RST indicators areas of local interest.
- The initial content is based on consideration of the indicators available within the ePACT2 system. There will be the option to include indicators from other information sources as this approach is developed.
- The RST does not state where best practice targets are for the indicators involved, in recognition of the fact that specific best practice positions may be dependent on local circumstances and therefore should be locally determined.
P1.85 The average number of unique medicines prescribed per patient - for patients ≥85 years old
P2.75 Percentage of patients with an anticholinergic burden score of 6 or more aged 75 and over
P3.9 Percentage of patients with an anticholinergic burden score ≥9
P4 Percentage of patients prescribed medicines likely to cause Acute Kidney Injury DAMN (Diuretics/ACI&ARBs/Metformin/NSAIDS) drugs
P5 Percentage of patients prescribed a NSAID and ≥ 1 other unique medicines likely to cause kidney injury (DAMN drugs)
P6 s Percentage of patients prescribed multiple anticoagulant regimes
Ref Gastrointestinal Bleed Risk
S1 (GIB01) Patients ≥65 years old prescribed a NSAID and NOT concurrently prescribed a gastro-protective medicine
S2 (GIB02) Patients ≥18 years old prescribed a NSAID and concurrently prescribed an oral anticoagulant (warfarin or NOAC)
S3 (GIB0) Patients ≥18 years old prescribed an oral anticoagulant (warfarin or a non-vitamin K antagonist oral anticoagulant (NOAC)) with an anti-platelet and NOT concurrently prescribed a gastroprotective medicine
S4 (GIB04) Patients ≥18 years old prescribed aspirin and another antiplatelet and NOT concurrently prescribed a gastro-protective medicine
S5 (GIBC1) Composite Gastro Intestinal Bleeds comprising of unique patients from indicators 1 to 4
S6 v Total volumes of oral NSAIDS (ADQs per STARPU)
R1 High dose ICS Inhaled Corticosteriod items as a % of all ICS items
R2 The proportion of patients receiving 5 or fewer prescription items of ICS LABA products over 12 months
R3 Asthma patients prescribed 6 or more SABA inhalers over 12 months